REGENXBIO (NASDAQ:RGNX) Upgraded to Hold at StockNews.com

REGENXBIO (NASDAQ:RGNX) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other research analysts have also weighed in on RGNX. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average price target of $33.45.

REGENXBIO Price Performance

Shares of RGNX traded down $0.21 during mid-day trading on Tuesday, reaching $6.72. The stock had a trading volume of 1,097,676 shares, compared to its average volume of 951,104. The firm has a market cap of $332.94 million, a price-to-earnings ratio of -1.34 and a beta of 1.29. The business’s fifty day moving average is $7.63 and its 200 day moving average is $9.52. REGENXBIO has a 52-week low of $6.44 and a 52-week high of $28.80.

Institutional Trading of REGENXBIO

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in REGENXBIO by 141.3% in the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares in the last quarter. FMR LLC raised its holdings in REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after purchasing an additional 17,563 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.